METiS Pharmaceuticals has revealed that its in-house-developed AiTEM artificial intelligence formulation innovation platform will be installed locally at Hengrui Medicine, aiming to boost the effectiveness of pharmaceutical formulation creation. This partnership represents an ongoing external commercialization of the AiTEM platform, which is underpinned by NanoForge, and also highlights the swift advancement of NanoForge as an AI4S (AI for Science) research and development framework. NanoForge, an AI nano-delivery platform independently crafted by METiS Pharmaceuticals, boasts an extensive repository of lipid structures and experimental data, underpinning numerous innovative drug development projects. Utilizing the NanoForge technology engine, the AiTEM platform facilitates the design and refinement of pharmaceutical formulations, substantially reducing the preclinical formulation optimization timeline. Industry analysts have noted that this collaboration signifies a shift in AI-driven drug development from isolated project partnerships to a new phase of platform-based outputs, affirming the industrial worth of METiS Pharmaceuticals' AI platform and aiding in the establishment of a scalable business model to encourage broader adoption of its AI research and development platform across the pharmaceutical industry.